Jeremiah E. Moore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeremiah E. Moore has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Clive S. Zent
Department of Medicine University of Rochester Medical Center Rochester New York United States
5 shared publications - AnnaLynn M. Williams
Division of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center , Rochester, NY
3 shared publications - Andrea Baran
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY 14642, USA
2 shared publications Andrea M. Baran
James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States; Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, United States
2 shared publicationsAndrew G. Evans
James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, United States
2 shared publicationsCarla Casulo
Division of Hematology/Oncology and Wilmot Cancer Institute University of Rochester School of Medicine and Dentistry Rochester NY
2 shared publications
Latest Publications
- Open Access
- 21 March 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (6)
Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
Background: There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting. Methods and Results: The study population comprised 2064 patients included in the University of Rochester Medical Center Lymphoma Database from January 2013 to August 2019. Cardiac arrhythmias—atrial fibrillation/flutter, supraventricular tachycardia, ventricular arrhythmia, and bradyarrhythmia—were identified using International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes. Multivariate Cox regression analysis was used to assess the risk of arrhythmic events with treatments categorized as Bruton tyrosine kinase inhibitor (BTKi), mainly ibrutinib/non‐BTKi treatment versus no treatment. Median age was 64 (54–72) years, and 42% were women. The overall rate of any arrhythmia at 5 years following the initiation of BTKi was (61%) compared with (18%) without treatment. Atrial fibrillation/flutter was the most common type of arrhythmia accounting for 41%. Multivariate analysis showed that BTKi treatment was associated with a 4.3‐fold ( P P P P <0.001). Conclusions: Our study identifies a high burden of arrhythmic events after initiation of treatment, which is most pronounced among patients treated with the BTKi ibrutinib. Patients undergoing treatments for lymphoma may benefit from prospective focused cardiovascular monitoring prior, during, and after treatment regardless of arrhythmia history.
- 21 March 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (6)
Open AccessArrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders
Background: There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real‐world setting. Methods and Results: The study population comprised 2064 patients included in the University of Rochester Medical Center Lymphoma Database from January 2013 to August 2019. Cardiac arrhythmias—atrial fibrillation/flutter, supraventricular tachycardia, ventricular arrhythmia, and bradyarrhythmia—were identified using International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes. Multivariate Cox regression analysis was used to assess the risk of arrhythmic events with treatments categorized as Bruton tyrosine kinase inhibitor (BTKi), mainly ibrutinib/non‐BTKi treatment versus no treatment. Median age was 64 (54–72) years, and 42% were women. The overall rate of any arrhythmia at 5 years following the initiation of BTKi was (61%) compared with (18%) without treatment. Atrial fibrillation/flutter was the most common type of arrhythmia accounting for 41%. Multivariate analysis showed that BTKi treatment was associated with a 4.3‐fold ( P P P P <0.001). Conclusions: Our study identifies a high burden of arrhythmic events after initiation of treatment, which is most pronounced among patients treated with the BTKi ibrutinib. Patients undergoing treatments for lymphoma may benefit from prospective focused cardiovascular monitoring prior, during, and after treatment regardless of arrhythmia history.
- 1 March 2021
- Published by Elsevier in Leukemia Research
- Vol. 102, 106522
Targeted therapy for treatment of patients with classical hairy cell leukemia
- 1 March 2021
- Published by Elsevier in Leukemia Research
- Vol. 102, 106522
Targeted therapy for treatment of patients with classical hairy cell leukemia
- Open Access
- 17 January 2020
- Published by Wiley in American Journal of Hematology
- Vol. 95 (5) , E108-E110
Initial treatment of B‐cell prolymphocytic leukemia with ibrutinib
- 17 January 2020
- Published by Wiley in American Journal of Hematology
- Vol. 95 (5) , E108-E110
Open AccessInitial treatment of B‐cell prolymphocytic leukemia with ibrutinib
- Open Access
- 17 October 2019
- Published by Wiley in American Journal of Hematology
- Vol. 95 (1) , E16-E18
Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy
- 17 October 2019
- Published by Wiley in American Journal of Hematology
- Vol. 95 (1) , E16-E18
Open AccessSignificant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy
- 1 January 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (1) , 41-47
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
- 1 January 2019
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 19 (1) , 41-47
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience
- 9 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , E542-E544
Ibrutinib therapy for lymphoplasmacytic lymphoma
- 9 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , E542-E544
Ibrutinib therapy for lymphoplasmacytic lymphoma